Skip to main content
Fig. 3 | Respiratory Research

Fig. 3

From: Vildagliptin ameliorates pulmonary fibrosis in lipopolysaccharide-induced lung injury by inhibiting endothelial-to-mesenchymal transition

Fig. 3

Vildagliptin suppressed EndMT in a mouse model of post-ALI pulmonary fibrosis. a Immunohistochemistry revealed that the number of CD31+/α-SMA+-cells (EndMT-cells) isolated from mice increased 28 days after LPS administration, and the increase could be significantly inhibited by systemic vildagliptin administration. CD31, green; α-SMA, red; Hoechst, blue. Scale bars, 100 μm. b Immunohistochemistry revealed that the number of CD31+/S100A4+-cells (EndMT-cells) was increased 28 days after LPS administration, and the increase could be significantly inhibited by systemic vildagliptin administration. CD31, green; S100A4, red; Hoechst, blue. Scale bars, 100 μm

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us